In later studies by Japanese researchers (Fukushima 1999; Fukushima et al. 2003, 2016; Hoshi et al. 2004; Wei et al. 2006), MeIQx was tested at much lower doses, but the biological endpoint quantified in the above-mentioned studies was the number of glutathione S-transferase P (GST-P)-positive foci per cm2 hepatic tissue instead of the incidence of hepatocellular carcinomas. The gene discussed is GSTP1; the disease is hepatocellular carcinoma.